Individualized treatment of osteoporosis

被引：0

作者：

Harbeck, B. ^{[1
]}

Lehnert, H. ^{[2
]}

机构：

[1] Univ Lubeck, Med Klin 1, Univ Klinikum Schleswig Holstein, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany

[2] Univ Lubeck, Prasidium, Lubeck, Germany

来源：

INTERNIST | 2016年 / 57卷 / 07期

关键词：

Osteoporosis; drug therapy; Age factors; Comorbidity; Risk assessment; Fracture prophylaxis; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE RISK; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; BISPHOSPHONATES; DENOSUMAB; TERIPARATIDE; EFFICACY; ALENDRONATE; PREVENTION;

D O I：

10.1007/s00108-016-0074-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteoporosis is the most common clinical disorder of bone metabolism. Treatment decisions should be made on an individual basis, taking into consideration the relative benefits and risks in different patient populations. Drug selection should be based on the form (primary/secondary) and severity of osteoporosis, age, sex, the specific contraindications and precautions for using the various available medications, and existing comorbidities.

引用

页码：638 / +

页数：7

共 50 条

[41] Current Treatment of Osteoporosis
Nallasivan, Subramanian
INDIAN JOURNAL OF RHEUMATOLOGY, 2019, 14 (01) : 57 - 60
[42] Update on osteoporosis treatment
Nogues, Xavier
Martinez-Laguna, Daniel
MEDICINA CLINICA, 2018, 150 (12): : 479 - 486
[43] Pharmacological treatment of osteoporosis
Chun, Sungwook
JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2019, 62 (10): : 542 - 550
[44] The Diagnosis and Treatment of Osteoporosis
Thomasius, Friederike
Kurth, Andreas
Baum, Erika
Drey, Michael
Maus, Uwe
Schmidmaier, Ralf
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2025, 122 (01): : 12 - 18
[45] Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene
Huang, Weng-Foung
Tsai, Yi-Wen
Wen, Yu-Wen
Hsiao, Fei-Yuan
Kuo, Ken N.
Tsai, Chia-Rung
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (01): : 57 - 63
[46] Is there a potential dual effect of denosumab for treatment of osteoporosis and sarcopenia?
El Miedany, Yasser
El Gaafary, Maha
Toth, Mathias
Hegazi, Mohamed Osama
El Aroussy, Nadia
Hassan, Waleed
Almedany, Samah
Nasr, Annie
Bahlas, Sami
Galal, Salwa
CLINICAL RHEUMATOLOGY, 2021, 40 (10) : 4225 - 4232
[47] Treatment of osteoporosis with denosumab
Lewiecki, E. Michael
MATURITAS, 2010, 66 (02) : 182 - 186
[48] Comparison of antiresorptive agents in the treatment of osteoporosis in older adults
Efendioglu, Eyyup Murat
Cigiloglu, Ahmet
Ganidagli, Sencer
Ozturk, Zeynel Abidin
CUKUROVA MEDICAL JOURNAL, 2022, 47 (03): : 1248 - 1255
[49] Risks vs. benefits of switching therapy in patients with postmenopausal osteoporosis
Ishizu, Hotaka
Arita, Kosuke
Terkawi, Mohamad Alaa
Shimizu, Tomohiro
Iwasaki, Norimasa
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2021, 16 (05) : 217 - 228
[50] The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis
Szulc, Pawel
CLINICAL BIOCHEMISTRY, 2012, 45 (12) : 907 - 919

← 1 2 3 4 5 →